Pfizer Reports P-III Study Results of Adcetris for Treating Diffuse Large B-cell Lymphoma (DLBCL)
Shots:
- Pfizer has revealed results from the P-III (ECHELON-3) trial assessing Adcetris + lenalidomide and rituximab vs PBO + lenalidomide and rituximab for treating r/r DLBCL (irrespective of CD30 expression) adult patients (n=230) not eligible for stem cell transplant or CAR-T therapy & who have been on two or more previous lines of treatment
- The results demonstrated an improved OS with Adcetris regimen vs PBO + lenalidomide & rituximab. The 2EPs of PFS and ORR were also met
- Adcetris’ safety & tolerability profiles were consistent with the previous r/r DLBCL studies of the drug. Further data will be highlighted at the upcoming medical meetings
Ref: Pfizer | Image: Pfizer
Related News:- Takeda’s Adcetris (brentuximab vedotin) Receives EC’s Approval for Previously Untreated CD30+ Stage III Hodgkin Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
